Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

  • Conferences
    • AACR21
    • AACR20
    • AACR19
    • AACR18
    • AACR17
    • AACR16
    • AACR15
    • AACR14
    • AACR IO
    • AAI ASGCT
    • ASCO GI
    • ASCO GU
    • ASCO-SITC
    • ASCO21
    • ASCO20
    • ASCO19
    • ASCO18
    • ASCO17
    • ASCO16
    • ASCO15
    • ASCO14
    • ASH21
    • ASH20
    • ASH19
    • ASH18
    • ASH17
    • ASH16
    • ASH15
    • AUA
    • BMT
    • CIML40
    • CIMT
    • EACR
    • EAU
    • ECCO
    • EHA iCML
    • ESMO21
    • ESMO20
    • ESMO19
    • ESMO18
    • ESMO17
    • ESMO16
    • ESMO14
    • JPM20
    • Mol Targets
    • SABCS
    • SITC 2020
    • SITC 2019
    • SITC 2018
    • SITC 2017
    • SITC 2016
    • SITC 2015
    • SITC 2014
  • Targets
    • Adenosine
    • AI & ML
    • Bispecifics
    • Cell Therapy
    • Cytokines
    • DDR
    • Epigenetics
    • gamma delta T cells
    • MYC
    • Neoantigens
    • NK Cells
    • RAS
    • SERDs
    • STING
    • TIGIT
    • TLRs
  • About
  • Contact
  • Pricing
  • Immuno-Oncology
  • Protein Degraders
  • Premium Content
  • Interviews
  • SITC 2021
  • Login

  • Can bispecifics succeed where ADCs have failed?

    Read more

  • New developments in the cell and gene therapy landscape

    Read more

  • Lessons learned from SITC – Part 1

    Read more

  • New trials and tribulations in drugging KRAS mutations

    Read more

  • An immunotherapy for the long run – or tail

    Read more

  • Scores on the doors in the TIGIT niche

    Read more

  • A review of the emerging bispecific landscape

    Read more
E

Can bispecifics succeed where ADCs have failed?

Finessing oncology targets can be both tricky and challenging. Does changing the modality help?

View post
E

New developments in the cell and gene therapy landscape

Novel approaches to fine tuning CAR-T cell therapies are hitting the clinic

View post
E

Lessons learned from SITC – Part 1

Sometimes we learn more from failure than we do from success

View post

Terms of Use & Privacy Policy
Copyright © 2010-21 Biotech Strategy Blog

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!